Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Agenovir

Agenovir?uq=w9if130k
2014 FOUNDED
PRIVATE STATUS
Series A LATEST DEAL TYPE
$10.6M LATEST DEAL AMOUNT
6 INVESTORS
Description

Developer of novel therapeutics designed to address diseases associated with or caused by, latent or persistent viral reservoirs. The company's novel therapeutics specialize in developing a novel class of nuclease-based anti-viral therapeutics to eliminate pathogenic viral genomes, enabling healthcare providers to treat their patients suffering from devastating and persistent viral infection.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Primary Office
  • 7000 Shoreline Court
  • Suite 320
  • South San Francisco, CA 94080
  • United States

+1 (650) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Agenovir’s full profile, request a free trial.

Agenovir Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series A) 17-May-2016 $10.6M 000.00 000.00 Completed Generating Revenue
3. Grant 01-Jan-2016 00000 Completed Generating Revenue
2. Accelerator/Incubator Completed Startup
1. Accelerator/Incubator Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Agenovir Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table, request access »

Agenovir Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Celgene Corporation Minority 000 0000 000000 0
Data Collective Venture Capital Minority 000 0000 000000 0
Lightspeed Venture Partners Venture Capital Minority 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
California Institute for Quantitative Biosciences Accelerator/Incubator 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Agenovir Executive Team (5)

Name Title Board
Seat
Contact
Info
Dirk Thye MD Chief Executive Officer, President and Board Member
Bolyn Hubby Ph.D Chief Scientific Officer
Stephen Quake Ph.D Co-Founder, Board Member & Chairman of the Scientific Advisory Board
Angela Wu Co-Founder & Advisor

1 Former Executive

You’re viewing 4 of 5 executives. Get the full list »

Agenovir Board Members (4)

Name Representing Role Since Contact
Info
Bruce Hironaka JD Agenovir Board Member 000 0000
Matthew Ocko Data Collective Board Member 000 0000
Stephen Quake Ph.D Agenovir Co-Founder, Board Member & Chairman of the Scientific Advisory Board 000 0000
William Smith Agenovir Board Member, Intellectual Property 000 0000